Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
AIP reported a proposed sale of 20,000 shares of Common Stock. The filing excerpt lists multiple 10b5-1 sales by BAYVIEW LEGACY, LLC on 01/08/2026, 01/15/2026, 02/09/2026, 03/09/2026, and others, with trade sizes such as 50,000 shares on 01/08/2026 and 41,000 shares on 03/09/2026. The excerpt also shows a 10b5-1 sale by K. CHARLES JANAC for 11,145 shares on 01/06/2026. Broker information lists Morgan Stanley Smith Barney LLC and a filing date of 03/25/2026.
Arteris, Inc. President and CEO Charles K. Janac reported open-market sales of a total of 50,000 shares of common stock through Bayview Legacy, LLC on March 9–10, 2026. The shares were sold at weighted average prices of $14.2104 and $14.663 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After the sales, indirect holdings through Bayview Legacy, LLC were 9,229,071 shares, in addition to 217,538 shares held directly and 56,252 shares held via the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of a total of 50,000 shares of common stock over two days. On March 9, 2026, it sold 41,000 shares at a weighted average price of $14.2104 per share, and on March 10, 2026 it sold 9,000 shares at a weighted average price of $14.6630. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted by K. Charles Janac as manager of Bayview Legacy, LLC. Following the transactions, Bayview Legacy, LLC held 9,229,071 Arteris common shares indirectly.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for the proposed resale of 20,000 Common shares related to an Nasdaq‑traded issuer, dated 03/09/2026.
The filing lists recent 10b5-1 brokered sales by related holders in the prior three months, including sales by BAYVIEW LEGACY, LLC of 50,000 shares on 01/08/2026 (proceeds $829,155.00) and 47,244 shares on 02/09/2026 (proceeds $718,359.19).
Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of 109,721 shares of common stock by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust. The trust sold 106,031 shares on March 2, 2026 at a weighted average price of $17.2127 and 3,690 shares on March 4, 2026 at a weighted average price of $17.0153, under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, the trust held 390,000 shares indirectly, and Raza also held 20,839 shares directly.
AIP reported sale notices and related 10b5-1 transactions. The filing lists an issuer notice to sell 90,000 common shares from previously exercised stock options dated 12/28/2020, and discloses 10b5-1 sales of common shares on 02/25/2026, 02/26/2026, and 02/27/2026.
The excerpt shows executed 10b5-1 trades of 4,907, 73,610, and 11,762 common shares (totaling 90,279 shares) with reported proceeds in dollars. Shares outstanding are listed as 45,467,261 as of 03/02/2026.
Arteris, Inc. director-related entity activity shows the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust selling a total of 90,279 shares of common stock in open-market transactions. These sales occurred on February 25–27, 2026 at weighted average prices around $17 per share under a pre-arranged Rule 10b5-1 trading plan.
After these indirect sales, the trust held 499,721 shares, while a separate direct holding for the reporting person stood at 20,839 shares of Arteris common stock as of February 25, 2026.
AIP reports a Form 144 notice to sell 110,000 common shares. The filing lists a broker (Morgan Stanley Smith Barney LLC) and references NASDAQ with a filing date of 02/25/2026. It cites two lots from prior option exercises: 65,000 (04/13/2015) and 45,000 (12/28/2020).
Arteris, Inc. major shareholder Bayview Legacy, LLC, a 10% owner, reported a bona fide gift transfer of 70,000 shares of Common Stock on February 20, 2026. Following this non-cash disposition, Bayview Legacy, LLC indirectly holds 9,279,071 Arteris shares, with voting and dispositive power exercised by its manager, K. Charles Janac.